ResearcherFujian Medical UniversityNo recent work listed

Xinfeng Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2329-1835; OpenAlex author ID A5101702531. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper

Papers 2

Echinacoside suppresses pancreatic adenocarcinoma cell growth by inducing apoptosis via the mitogen-activated protein kinase pathway. Last author DOI 10.3892/mmr.2016.4867 ↗
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0074272 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wei J. Wang · 1 shared paper, 2016 · strength 0.08
- Paper Echinacoside suppresses pancreatic adenocarcinoma cell growth by inducing apoptosis via the mitogen-activated protein k… DOI 10.3892/mmr.2016.4867 ↗
Paul Okunieff · 1 shared paper, 2013 · strength 0.03
- Paper Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer. DOI 10.1371/journal.pone.0074272 ↗
Lurong Zhang · 1 shared paper, 2013 · strength 0.03
- Paper Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer. DOI 10.1371/journal.pone.0074272 ↗
Wei Wang · 1 shared paper, 2013 · strength 0.03
- Paper Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer. DOI 10.1371/journal.pone.0074272 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.